文献速递乳腺癌头颈与中枢神经肿瘤

已发表列线图对脑外转移性乳腺癌患者脑转移预测的外部验证及风险回归分析

External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.
PubMed 文献 · Eur J Cancer · 2016-12-30

本研究对2010年发表的Graesslin列线图进行外部验证,回顾性纳入2005年1月至2012年12月在本机构治疗的乳腺癌后发脑转移患者。492例转移性乳腺癌中116例发生后续脑转移,其中70例纳入列线图验证,区分度良好(曲线下面积=0.695[95%CI 0.61-0.77])。竞争风险分析显示列线图仅对HER2阳性肿瘤亚组有预测价值。

要点

  • Graesslin列线图外部验证区分度良好,曲线下面积=0.695(95%CI 0.61-0.77)。
  • 脑转移风险因素包括HER2过表达/扩增、三阴性乳腺癌及脑外转移部位数>1。
  • 竞争风险模型显示列线图仅对HER2阳性肿瘤亚组有预测意义。

核心结论

  • Graesslin列线图外部验证显示其具有可移植性和可重复性。
  • 竞争风险模型分析为设计脑转移早期诊断和/或高危脑外转移性乳腺癌患者预防性治疗的前瞻性试验提供了额外信息。

研究设计与样本

  • 回顾性外部验证研究,纳入2005年1月至2012年12月在本机构治疗的乳腺癌后发脑转移患者。
  • 492例转移性乳腺癌患者中116例发生后续脑转移,其中70例纳入列线图验证。
  • 采用Fine和Gray竞争风险分析研究脑转移出现的风险因素。

主要发现

  • 列线图区分度良好,曲线下面积=0.695(95%CI 0.61-0.77)。
  • 脑转移出现的风险因素为:人表皮生长因子受体2(HER2)过表达/扩增、三阴性乳腺癌、脑外转移部位数>1。
  • 竞争风险模型显示列线图的预测价值仅见于HER2阳性肿瘤亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival of patients with metastatic breast cancer (MBC) suffering from brain metastasis (BM) is limited and this event is usually fatal. In 2010, the Graesslin's nomogram was published in order to predict subsequent BM in patients with breast cancer (BC) with extra-cerebral metastatic disease. This model aims to select a patient population at high risk for BM and thus will facilitate the design of prevention strategies and/or the impact of early treatment of BM in prospective clinical studies. PATIENTS AND METHODS: Nomogram external validation was retrospectively applied to patients with BC and later BM between January 2005 and December 2012, treated in our institution. Moreover, risk factors of BM appearance were studied by Fine and Gray's competing risk analysis. RESULTS: Among 492 patients with MBC, 116 developed subsequent BM. Seventy of them were included for the nomogram validation. The discrimination is good (area under curve = 0.695 [95% confidence interval, 0.61-0.77]). Risk factors of BM appearance are: human epidermal growth factor receptor 2 (HER2) overexpression/amplification, triple-negative BC and number of extra-cerebral metastatic sites (>1). With a competing risk model, we highlight the nomogram interest for HER2+ tumour subgroup exclusively. CONCLUSION: Graesslin's nomogram external validation demonstrates exportability and reproducibility. Importantly, the competing risk model analysis provides additional information for the design of prospective trials concerning the early diagnosis of BM and/or preventive treatment on high risk patients with extra-cerebral metastatic BC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Genre L, Roché H, Varela L, et al. External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis. Eur J Cancer. 2016. PMID: 28042991. doi:10.1016/j.ejca.2016.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。